BR112022020965A2 - Derivados de piridopirimidinona e seu uso como moduladores de receptores de hidrocarboneto arila - Google Patents

Derivados de piridopirimidinona e seu uso como moduladores de receptores de hidrocarboneto arila

Info

Publication number
BR112022020965A2
BR112022020965A2 BR112022020965A BR112022020965A BR112022020965A2 BR 112022020965 A2 BR112022020965 A2 BR 112022020965A2 BR 112022020965 A BR112022020965 A BR 112022020965A BR 112022020965 A BR112022020965 A BR 112022020965A BR 112022020965 A2 BR112022020965 A2 BR 112022020965A2
Authority
BR
Brazil
Prior art keywords
aryl hydrocarbon
hydrocarbon receptor
ahr
receptor modulators
disease
Prior art date
Application number
BR112022020965A
Other languages
English (en)
Inventor
Song Minsoo
Young Park Ga
Kang Jihee
Lee Eunhye
Park Yoojin
Choi Yujeong
Kim Soong-Hyun
Bi Ko Eun
Bae Seri
Park Jung-Sang
Cha Daewon
Lee Wonhyung
Sung Joo Min
Yoon Taeyoung
Doh Hyounmie
Ryeong Lee Bo
Jung Sung Hyun
Kim Yoonjung
Original Assignee
Dong A St Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A St Co Ltd filed Critical Dong A St Co Ltd
Publication of BR112022020965A2 publication Critical patent/BR112022020965A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

DERIVADOS DE PIRIDOPIRIMIDINONA E SEU USO COMO MODULADORES DE RECEPTORES DE HIDROCARBONETO ARILA. A presente invenção se refere a compostos inovadores eficazes como moduladores do receptor de hidrocarboneto de arila (AhR), composição farmacêutica que compreende os compostos para a modulação de AhR ou prevenção ou tratamento de uma doença, distúrbio ou condição associada à atividade de AhR, como ingrediente ativo, e assim, pode ser útil como um medicamento para a prevenção ou tratamento de uma doença, distúrbio ou condição associada à atividade de AhR, em particular, câncer, condição cancerosa, tumor, doença fibrótica, condição com respostas imunes desreguladas, etc.
BR112022020965A 2020-04-17 2021-04-19 Derivados de piridopirimidinona e seu uso como moduladores de receptores de hidrocarboneto arila BR112022020965A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011351P 2020-04-17 2020-04-17
PCT/KR2021/004904 WO2021210970A1 (en) 2020-04-17 2021-04-19 Pyridopyrimidinone derivatives and their use as aryl hydrocarbon receptor modulators

Publications (1)

Publication Number Publication Date
BR112022020965A2 true BR112022020965A2 (pt) 2022-12-06

Family

ID=78084339

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020965A BR112022020965A2 (pt) 2020-04-17 2021-04-19 Derivados de piridopirimidinona e seu uso como moduladores de receptores de hidrocarboneto arila

Country Status (10)

Country Link
US (1) US20230147257A1 (pt)
EP (1) EP4136088A4 (pt)
JP (1) JP2023522045A (pt)
KR (1) KR20230005188A (pt)
CN (1) CN115443276A (pt)
AU (1) AU2021257373B2 (pt)
BR (1) BR112022020965A2 (pt)
CA (1) CA3178129A1 (pt)
MX (1) MX2022012739A (pt)
WO (1) WO2021210970A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021102288A1 (en) * 2019-11-22 2021-05-27 Senda Biosciences, Inc. Pyridopyrimidinone derivatives as ahr antagonists
CN114644627A (zh) * 2020-12-18 2022-06-21 山东轩竹医药科技有限公司 AhR抑制剂及其用途
WO2022217042A1 (en) * 2021-04-09 2022-10-13 Ikena Oncology, Inc. Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
WO2024008722A2 (en) * 2022-07-04 2024-01-11 Muna Therapeutics Aps Trem2 modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102227221A (zh) * 2008-11-28 2011-10-26 诺瓦提斯公司 包含hsp90抑制剂和mtor抑制剂的药物组合
CN106536520B (zh) * 2014-06-27 2020-08-14 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
TW201942115A (zh) * 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
US10815250B2 (en) * 2018-02-06 2020-10-27 Ideaya Biosciences, Inc. AhR modulators
AU2019323714A1 (en) * 2018-08-24 2021-03-25 Jaguahr Therapeutics Pte Ltd Tetrahydropyridopyrimidine derivatives as AhR modulators
CN113260609A (zh) * 2018-09-04 2021-08-13 美真达治疗公司 芳烃受体拮抗剂及其使用方法
CN111961034A (zh) * 2019-05-20 2020-11-20 浙江同源康医药股份有限公司 用作ret激酶抑制剂的化合物及其应用
WO2021102288A1 (en) * 2019-11-22 2021-05-27 Senda Biosciences, Inc. Pyridopyrimidinone derivatives as ahr antagonists
CN116745622A (zh) * 2020-10-13 2023-09-12 先达生物科技公司 与免疫检查点抑制剂疗法相关的生物标志物及其使用方法
CN114644627A (zh) * 2020-12-18 2022-06-21 山东轩竹医药科技有限公司 AhR抑制剂及其用途

Also Published As

Publication number Publication date
EP4136088A1 (en) 2023-02-22
CA3178129A1 (en) 2021-10-21
MX2022012739A (es) 2022-11-07
EP4136088A4 (en) 2024-05-08
KR20230005188A (ko) 2023-01-09
US20230147257A1 (en) 2023-05-11
CN115443276A (zh) 2022-12-06
WO2021210970A1 (en) 2021-10-21
AU2021257373A1 (en) 2022-10-20
JP2023522045A (ja) 2023-05-26
AU2021257373B2 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
BR112022020965A2 (pt) Derivados de piridopirimidinona e seu uso como moduladores de receptores de hidrocarboneto arila
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
Niehr et al. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
Macias et al. Low-level laser therapy at 635 nm for treatment of chronic plantar fasciitis: a placebo-controlled, randomized study
BR112022020841A2 (pt) Inibidores de kras tricíclicos fundidos
BR112021022778A2 (pt) Compostos e métodos para o tratamento de covid-19
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BRPI0606707A2 (pt) uréias dissubstituìdas como inibidores de quinase
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
BR112022002237A2 (pt) Tratamento de distúrbios do sistema nervoso central
BR112021016833A2 (pt) Compostos com atividade indutora de ferroptose e métodos de seu uso
BR112021016296A2 (pt) Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele
CL2023000881A1 (es) Compuestos y su uso en el tratamiento del cáncer
BR112022023983A2 (pt) Compostos terapêuticos
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112022009805A2 (pt) Derivados de piridopirimidinona como antagonistas de ahr
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
BR112022014968A2 (pt) Composto, composição farmacêutica e métodos de inibição do nível de brd9 em uma célula, de inibição da atividade de brd9 em uma célula, de tratamento de um distúrbio, de tratamento de um câncer em um sujeito em necessidade e de tratamento de infecção em um sujeito em necessidade
BR112022011321A2 (pt) Compostos, polímeros, dispositivos e seus usos
BR112022024045A2 (pt) Moduladores il-17a
BR112021018591A2 (pt) Compostos e usos dos mesmos
BR112023001143A2 (pt) Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo
BR112013024909A2 (pt) composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k
Steffen et al. Botulinum toxin for salivary disorders in the treatment of head and neck cancer
Sollie et al. Autologous fat grafting seems to alleviate postherpetic neuralgia–a feasibility study investigating patient-reported levels of pain